Diffusion Pharmaceuticals Inc (DFFN) |
|
0.83 0.035 (4.34%)
|
09-27 22:15 |
|
Open: |
0.81 |
Pre. Close: |
0.7955 |
|
High:
|
0.8673 |
Low:
|
0.772 |
|
Volume:
|
1,575,119 |
Market Cap:
|
53M |
|
|
|
|
Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. The company is headquartered in Charlottesville, Virginia and currently employs 10 full-time employees. The firm is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The firm's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The firm's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.872 - 0.878 |
0.878 - 0.883 |
|
Low:
|
0.757 - 0.764 |
0.764 - 0.77 |
|
Close:
|
0.819 - 0.83 |
0.83 - 0.84 |
|
Technical analysis |
as of: 2020-09-25 4:29:04 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 1.16  One year: 1.33 |
| Support: |
Support1: 0.75 Support2: 0.62 |
| Resistance: |
Resistance1: 0.99 Resistance2: 1.14 |
| Pivot: |
0.86 |
| Moving Average: |
MA(5): 0.82 MA(20): 0.88
MA(100): 1.02 MA(250): 0.76 |
| MACD: |
MACD(12,26): -0.05 Signal(9): -0.05 |
| Stochastic oscillator: |
%K(14,3): 23.46 %D(3): 23.87 |
| RSI: |
RSI(14): 40.09 |
| 52-week: |
High: 1.97 Low: 0.21 Change(%): -55.1 |
| Average Vol(K): |
3-Month: 242966 10-Days: 131376 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.DFFN has closed above bottom band by 36.2%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to DFFN's normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 25 Sep 2020
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Stock Jumped 72.67% Year-To-Date, What Analysts Expect Next? - Marketing Sentinel
Fri, 25 Sep 2020
Diffusion Pharmaceuticals (NASDAQ:DFFN) Creates a Treatment to Improve Oxygenation - The Wall Street Transcript
Thu, 24 Sep 2020
Are Shares Of Diffusion Pharmaceuticals Inc. (DFFN) Really Worth? - investmillion.com
Wed, 23 Sep 2020
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) on the Path to Ruin - The Oracle Dispatch
Tue, 15 Sep 2020
Diffusion Pharmaceuticals Inc. (DFFN) EPS is poised to hit -0.07 next quarter: How Investors Can Make It Count the Most? - News Daemon
Fri, 11 Sep 2020
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) is Waving the Bear Flag - The Oracle Dispatch
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
64 |
| Shares Float (M) |
64 |
|
% Held by Insiders
|
0.23 |
|
% Held by Institutions
|
13.33 |
|
Shares Short (K)
|
847 |
|
Shares Short P. Month (K)
|
737 |
Stock Financials |
|
EPS
|
-0.536 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
0.510 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-28.7 |
|
Return on Equity (ttm)
|
-49.9 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.196 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-11 |
|
Levered Free Cash Flow (M)
|
-7 |
Stock Valuations |
|
PE Ratio
|
-1.55 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.63 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-4.73 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
